Microarray Companies Click on Capital In the First Calendar Quarter of 2004 | GenomeWeb

For the microarray industry, the first quarter of the financial year 2004 was one marked by an apparent easing of access to financial capital as companies such as Nanogen, Lynx, and Zyomyx took in some $49.5 million in new capital. Nanogen secured a private placement of $30 million (see BAN 3/10/2004), while Lynx completed two private placements of $4 million each. Meanwhile, on the private equity side, six-year-old protein-microarray developer Zyomyx closed on a $10 million sixth round of funding in February (see BAN 2/18/2004).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.